Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

This study has been completed.
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
First received: May 30, 2006
Last updated: June 11, 2008
Last verified: June 2008
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Condition Intervention Phase
Allergic Conjunctivitis
Drug: olopatadine 0.2%
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Daily signs and symptoms scores during the 14 days of peak pollen

Secondary Outcome Measures:
  • Patients with daily signs and symptoms scores of zero during the 14 days of peak pollen

Estimated Enrollment: 250
Study Start Date: August 2006
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model

Exclusion Criteria:

  • Under 10 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00331500

United States, Texas
Alcon Research, Ltd.
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
Study Director: Stella Robertson Study Director
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00331500     History of Changes
Other Study ID Numbers: C-04-60
Study First Received: May 30, 2006
Last Updated: June 11, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Analgesics, Non-Narcotic
Anti-Allergic Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Histamine H1 Antagonists, Non-Sedating
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 30, 2015